HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback